ANTX
Price
$5.41
Change
-$0.28 (-4.92%)
Updated
Sep 11 closing price
Capitalization
204.15M
54 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$58.65
Change
-$0.15 (-0.26%)
Updated
Sep 11 closing price
Capitalization
5.68B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANTX vs XENE

ANTX vs XENE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANTX vs. XENE commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a StrongBuy and XENE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($5.68B) has a higher market cap than ANTX($204M). ANTX YTD gains are higher at: 374.561 vs. XENE (30.857). ANTX has higher annual earnings (EBITDA): -38.81M vs. XENE (-439.19M). XENE has more cash in the bank: 931M vs. ANTX (78.4M). ANTX (0) and XENE (0) have equivalent revenues.
ANTXXENEANTX / XENE
Capitalization204M5.68B4%
EBITDA-38.81M-439.19M9%
Gain YTD374.56130.8571,214%
P/E RatioN/AN/A-
Revenue00-
Total Cash78.4M931M8%
Total DebtN/A6.42M-
FUNDAMENTALS RATINGS
ANTX vs XENE: Fundamental Ratings
ANTX
XENE
OUTLOOK RATING
1..100
8184
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3544
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
5675

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANTX's Valuation (24) in the Managed Health Care industry is somewhat better than the same rating for XENE (79) in the Biotechnology industry. This means that ANTX’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for ANTX (100) in the Managed Health Care industry. This means that XENE’s stock grew significantly faster than ANTX’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as ANTX (98) in the Managed Health Care industry. This means that XENE’s stock grew similarly to ANTX’s over the last 12 months.

ANTX's Price Growth Rating (35) in the Managed Health Care industry is in the same range as XENE (44) in the Biotechnology industry. This means that ANTX’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ANTX (100) in the Managed Health Care industry. This means that XENE’s stock grew significantly faster than ANTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANTXXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
69%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
70%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (ANTX: $5.41 vs. XENE: $58.65)
Brand notoriety: ANTX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 47% vs. XENE: 49%
Market capitalization -- ANTX: $204.15M vs. XENE: $5.68B
ANTX [@Biotechnology] is valued at $204.15M. XENE’s [@Biotechnology] market capitalization is $5.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green while XENE’s FA Score has 2 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than ANTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 1 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • ANTX’s TA Score: 1 bullish, 5 bearish.
  • XENE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, XENE is a better buy in the short-term than ANTX.

Price Growth

ANTX (@Biotechnology) experienced а -8.15% price change this week, while XENE (@Biotechnology) price change was -1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

ANTX is expected to report earnings on Nov 05, 2026.

XENE is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ANTX
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSWCX16.680.18
+1.10%
Fidelity SAI US Value Index
FCGEX21.230.15
+0.71%
NYLIM PineStone Global Equity Class A
ALCEX20.050.13
+0.65%
Avantis U.S. Large Cap Value G
JSECX12.12N/A
N/A
JPMorgan Small Cap Equity C
FSBLX23.76N/A
N/A
Federated Hermes Global Allocation R6

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with XENE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
-4.92%
XENE - ANTX
46%
Loosely correlated
-0.26%
DNTH - ANTX
36%
Loosely correlated
+2.83%
RLMD - ANTX
35%
Loosely correlated
+11.06%
SLDB - ANTX
31%
Poorly correlated
-4.08%
PASG - ANTX
31%
Poorly correlated
+0.30%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.26%
RLMD - XENE
55%
Loosely correlated
+11.06%
ANTX - XENE
46%
Loosely correlated
-4.92%
MLTX - XENE
44%
Loosely correlated
-5.08%
DNTH - XENE
43%
Loosely correlated
+2.83%
REPL - XENE
42%
Loosely correlated
-2.42%
More